Rapid Expansion of Intravitreal Drug Injection Procedures, 2000 to 2008
Open Access
- 1 March 2010
- journal article
- socioeconomics and-health-services
- Published by American Medical Association (AMA) in American Journal of Ophthalmology
- Vol. 128 (3), 359-362
- https://doi.org/10.1001/archophthalmol.2010.19
Abstract
The development of vascular endothelial growth factor (VEGF) inhibitors has revolutionized the treatment of age-related macular degeneration (AMD), the leading cause of blindness in Western nations.1-3 The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD2 and the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD trial3 have demonstrated that the VEGF inhibitor ranibizumab not only slows vision loss but also improves visual acuity in many patients with neovascular AMD.Keywords
This publication has 5 references indexed in Scilit:
- Risk Factors for Acute Endophthalmitis after Cataract Surgery: A Population-based StudyOphthalmology, 2009
- A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial designTrials, 2008
- Intravitreal Steroids for Macular Edema: The Past, the Present, and the FutureSurvey of Ophthalmology, 2008
- Drug delivery methods for posterior segment diseaseCurrent Opinion in Opthalmology, 2007
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular DegenerationOphthalmic Surgery, Lasers and Imaging Retina, 2005